BPDCN: Future Directions in Care
Closing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Emerging Therapies in BPDCN
Shared insight on a number of novel therapies and treatment modalities being investigated in patients with blastic plasmacytoid dendritic cell neoplasm.
Sequencing Therapy in BPDCN in the Second Line and Beyond
Comprehensive insight on the sequencing of agents in BPDCN management, followed by considerations for use of stem cell transplant in this setting.
Patient Case 3: A 57-Year-Old Man With Relapsed BPDCN
Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.
Patient Case 2: A 22-Year-Old Woman With BPDCN
Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.
Factors in Selecting Optimal First-Line Therapy for BPDCN
Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.
Management of Capillary Leak Syndrome in BPDCN
A brief review of the identification and management of capillary leak syndrome in patients being treated for blastic plasmacytoid dendritic cell neoplasm.
A Role for Tagraxofusp in First-Line Setting in BPDCN
Expert perspectives on the first-line use of tagraxofusp, a CD123-directed therapy, in patients with blastic plasmacytoid dendritic cell neoplasm.
Patient Case 1: A 71-Year Old Man With BPDCN
Centering discussion on the first patient case of BPDCN, expert panelists highlight various assessment tools that may help overcome barriers to an early diagnosis.
Identification and Classification of BPDCN
Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.
Update Shows Long-Term Benefits of Tagraxofusp in BPDCN
Naveen Pemmaraju, MD discusses the long-term results of the STML-401-0114 trial that demonstrated the benefits of tagraxofusp-ezrs as a monotherapy for patients with blastic plasmacytoid dendritic cell neoplasms.
BPDCN: Epidemiology, Pathophysiology, and Diagnosis
Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.
Major Unmet Needs in Myeloproliferative Neoplasm Management
Naveen Pemmaraju, MD, shares the critical unmet needs in the myeloproliferative neoplasm treatment landscape.
Single-Agent Investigational Therapies for Myeloproliferative Neoplasms
A key opinion leader details the single-agent therapies currently being investigated for the treatment of myeloproliferative neoplasms.
Ruxolitinib Combination Therapies for Myeloproliferative Neoplasms
Dr Pemmaraju explains the rationale for ruxolitinib combination therapies in myeloproliferative neoplasm treatment.
Approved Systemic Treatment Options for Myelofibrosis
Naveen Pemmaraju, MD, reviews the currently approved systemic treatment options for myelofibrosis and explains how he decides between treatment regimens.
Overview of Myelofibrosis and the Challenges of Diagnosis
An expert gives an overview of myelofibrosis and its different types and describes the common challenges of diagnosing patients.
Current Standards of Care for Polycythemia Vera and Essential Thrombocytosis
Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.
Overview of the Types of Myeloproliferative Neoplasms
Naveen Pemmaraju, MD, provides an overview of the three classes of myeloproliferative neoplasms and the signaling pathways that drive therapeutic investigation in the field.
Investigational Agents and Unmet Needs in Myelofibrosis Treatment
Dr Naveen Pemmaraju discusses exciting potential treatment options in myelofibrosis and some unmet needs and ongoing challenges in the treatment landscape.
Potential Implications of the REFINE Trial on the Myelofibrosis Treatment Paradigm
Naveen Pemmaraju, MD, talks about the potential implications of the phase II REFINE trial on the myelofibrosis treatment paradigm.
Study Design and Outcomes of the Phase II REFINE Trial
A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.
Current Treatment Options in Myelofibrosis
Naveen Pemmaraju, MD, describes the currently available treatment options for patients with myelofibrosis.
The Role of Biomarker Testing in Patients with Myelofibrosis
Dr Naveen Pemmaraju explains the relationship of the JAK/STAT pathway to myelofibrosis and the molecular mutations he looks for with biomarker testing.
An Overview of Myelofibrosis
Naveen Pemmaraju, MD, provides an overview of myelofibrosis, including a comparison of primary and secondary myelofibrosis and the risk stratification.
Ruxolitinib/Navitoclax Shows Efficacy in Relapsed/Refractory Myelofibrosis
Naveen Pemmaraju, MD, discusses the results of combining ruxolitinib and navitoclax in different high-risk populations of relapsed/refractory myelofibrosis.
Pemmaraju Highlights Next Steps for Research in Myelofibrosis
Naveen Pemmaraju, MD, discusses the next steps for research in the field of myelofibrosis.
Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Evidence Supports Rechallenging of JAK Inhibitors in Myelofibrosis
Naveen Pemmaraju, MD, discusses the clinical implications of a retrospective analysis of 26 patients with myelofibrosis who received benefit from ruxolitinib when it was rechallenged.
Evaluating Prognosis and Treatment Options for Patients With Myelofibrosis
Naveen Pemmaraju, MD, discusses the current understandings of how myelofibrosis presents in patients.
2 Clarke Drive Cranbury, NJ 08512